Linagliptin vs Sitagliptin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline

Linagliptin · Tradjenta

Marketed by Boehringer Ingelheim and partners

Approved in Type 2 Diabetessmall molecule
Partial signal

NCT00602472 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial with 1,058 participants, and its primary endpoint was met: adjusted HbA1c change was −0.72% with linagliptin versus −0.10% with placebo (p<0.0001). The evidence is considered moderate because HbA1c is a surrogate measure rather than a hard clinical endpoint.

Reported efficacy

The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years (met)

Result source: NCT01243424

Sitagliptin · Januvia

Marketed by Merck & Co. and partners

Approved in Type 2 Diabetessmall molecule
Partial signal

NCT00087516 · Phase 3 · completed

The trial randomized 741 participants to double-blind sitagliptin or placebo groups, providing a substantial controlled comparison. The primary endpoint, change in A1C at week 24, was statistically favorable for both sitagliptin doses (p<0.001), but A1C is a surrogate endpoint, so the evidence is rated moderate rather than strong.

Next expected readout: September 2029 · NCT07108985 (registry estimate)

Reported efficacy

Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03) (met)

Result source: NCT00086502

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLinagliptinSitagliptin
HbA1c, change-0.6% vs 0.1%−0.6 vs placebo5 mg · wk 24 · n 618NCT00954447
129 other results
  • -0.7% vs -0.1% wk 24 · n 778 · Phase 3 · primary NCT00602472
  • -0.5% vs 0.1% wk 24 · n 513 · Phase 3 · primary NCT00601250
  • -0.6% vs -0.0% 5 mg · wk 24 · n 161 · Phase 3 · primary NCT01792518
  • -0.7% vs -0.2% 5 mg · wk 24 · n 196 · Phase 3 · primary NCT01214239
  • -0.7% vs -0.1% 5 mg once daily · wk 24 · n 203 · Phase 3 · primary NCT01215097
  • -0.8% vs -0.3% 5 mg tablet · wk 24 · n 179 · Phase 3 · primary NCT00996658
  • -0.8% vs -0.3% 5 mg · wk 24 · n 93 · Phase 3 · primary NCT01194830
  • -0.6% vs 0.0% 5 mg · wk 24 · n 160 · Phase 3 · primary NCT01084005
  • -0.5% vs -0.1% 5 mg · wk 12 · n 113 · Phase 3 · primary NCT01087502
  • -1.1% vs -0.6% wk 24 · n 252 · Phase 3 · primary NCT00641043
  • -0.4% vs 0.3% wk 24 · n 333 · Phase 3 · primary NCT00621140
  • -0.9% vs -0.3% 25 mg + 5 mg · wk 24 · n 111 · Phase 3 · primary NCT02489968
  • -0.6% vs 0.1% 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · primary NCT01734785
  • -0.9% vs -0.3% 10 mg + 5 mg · wk 24 · n 103 · Phase 3 · primary NCT02489968
  • -0.7% vs 0.1% 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · primary NCT01734785
  • -0.6% vs -0.2% wk 24 · n 100 · Phase 3 · primary NCT02897349
  • -0.4% vs -0.7% 5 mg · wk 30 · n 130 · Phase 3 · primary NCT01183013
  • 0.3% vs -0.2% 5 mg · wk 26 · n 52 · Phase 3 · primary NCT03429543
  • -1.3% vs -1.6% 5 mg QD · wk 24 · n 141 · Phase 3 · primary NCT01708902
  • -1.3% vs -1.7% 5 mg QD · wk 24 · n 125 · Phase 3 · primary NCT01708902
  • -0.8% vs -0.7% 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · primary NCT01183013
  • -1.1% vs -0.7% 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · primary NCT01183013
  • -1.3% vs -0.7% 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · primary NCT01183013
  • -2.1% vs -1.6% 2.5 mg / 500 mg BID · wk 24 · n 142 · Phase 3 · primary NCT01708902
  • -2.3% vs -1.6% 2.5 mg / 1000 mg BID · wk 24 · n 141 · Phase 3 · primary NCT01708902
  • -2.2% vs -1.7% 2.5 mg / 500 mg BID · wk 24 · n 135 · Phase 3 · primary NCT01708902
  • -2.4% vs -1.7% 2.5 mg / 1000 mg BID · wk 24 · n 128 · Phase 3 · primary NCT01708902
  • -0.5% vs 0.1% 5 mg · wk 52 · n 618 · Phase 3 · secondary NCT00954447
  • -0.5% vs 0.1% 5 mg · wk 40 · n 618 · Phase 3 · secondary NCT00954447
  • -0.6% vs 0.0% 5 mg · wk 32 · n 618 · Phase 3 · secondary NCT00954447
  • -0.6% vs 0.0% 5 mg · wk 18 · n 618 · Phase 3 · secondary NCT00954447
  • -0.6% vs 0.0% 5 mg · wk 12 · n 618 · Phase 3 · secondary NCT00954447
  • -0.5% vs 0% 5 mg · wk 6 · n 618 · Phase 3 · secondary NCT00954447
  • -0.8% vs -0.1% wk 18 · n 778 · Phase 3 · secondary NCT00602472
  • -0.7% vs -0.2% 5 mg · wk 24 · n 168 · Phase 3 · secondary NCT01214239
  • -0.7% vs -0.2% 5 mg once daily · wk 24 · n 182 · Phase 3 · secondary NCT01215097
  • -0.7% vs -0.2% 5 mg · wk 18 · n 196 · Phase 3 · secondary NCT01214239
  • -0.6% vs -0.1% 5 mg once daily · wk 18 · n 203 · Phase 3 · secondary NCT01215097
  • -0.9% vs -0.4% 5 mg tablet · wk 18 · n 179 · Phase 3 · secondary NCT00996658
  • -0.8% vs -0.3% 5 mg · wk 18 · n 93 · Phase 3 · secondary NCT01194830
  • -0.6% vs 0.0% 5 mg · wk 18 · n 160 · Phase 3 · secondary NCT01084005
  • -0.6% vs -0.1% 5 mg · wk 12 · n 196 · Phase 3 · secondary NCT01214239
  • -0.7% vs -0.1% 5 mg once daily · wk 12 · n 203 · Phase 3 · secondary NCT01215097
  • -0.8% vs -0.3% 5 mg tablet · wk 12 · n 179 · Phase 3 · secondary NCT00996658
  • -0.7% vs -0.2% 5 mg · wk 12 · n 93 · Phase 3 · secondary NCT01194830
  • -0.6% vs -0.0% 5 mg · wk 12 · n 160 · Phase 3 · secondary NCT01084005
  • -0.5% vs -0.1% 5 mg · wk 6 · n 196 · Phase 3 · secondary NCT01214239
  • -0.5% vs -0.0% 5 mg once daily · wk 6 · n 203 · Phase 3 · secondary NCT01215097
  • -0.6% vs -0.2% 5 mg tablet · wk 6 · n 179 · Phase 3 · secondary NCT00996658
  • -0.5% vs 0.1% wk 18 · n 513 · Phase 3 · secondary NCT00601250
  • -0.4% vs -0.1% 5 mg · wk 6 · n 160 · Phase 3 · secondary NCT01084005
  • -1.1% vs -0.6% wk 18 · n 252 · Phase 3 · secondary NCT00641043
  • -0.5% vs 0.2% wk 18 · n 333 · Phase 3 · secondary NCT00621140
  • -0.8% vs -0.1% wk 12 · n 778 · Phase 3 · secondary NCT00602472
  • -0.5% vs 0.1% wk 12 · n 513 · Phase 3 · secondary NCT00601250
  • -0.8% vs -0.3% wk 12 · n 252 · Phase 3 · secondary NCT00641043
  • -0.5% vs 0.2% wk 12 · n 333 · Phase 3 · secondary NCT00621140
  • -0.7% vs -0.2% wk 6 · n 778 · Phase 3 · secondary NCT00602472
  • -0.4% vs 0.1% wk 6 · n 513 · Phase 3 · secondary NCT00601250
  • -0.4% vs -0.0% wk 6 · n 252 · Phase 3 · secondary NCT00641043
  • -0.4% vs 0.1% wk 6 · n 333 · Phase 3 · secondary NCT00621140
  • -0.6% vs -0.2% 5 mg · wk 6 · n 93 · Phase 3 · secondary NCT01194830
  • -0.5% vs 0.1% 5 mg · wk 26 · n 5 · Phase 3 · secondary NCT03429543
  • 0.1% vs 0.1% wk 432 · n 2951 · Phase 3 · secondary NCT01243424
  • -0.4% vs -0.3% 5 mg · wk 52 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.2% 5 mg · wk 46 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.2% 5 mg · wk 40 · n 113 · Phase 3 · secondary NCT01087502
  • -0.5% vs -0.4% 5 mg · wk 34 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.7% 5 mg · wk 30 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.5% 5 mg · wk 28 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.7% 5 mg · wk 24 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.5% 5 mg · wk 24 · n 113 · Phase 3 · secondary NCT01087502
  • -0.5% vs -0.5% 5 mg · wk 20 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.6% 5 mg · wk 18 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.3% 5 mg · wk 16 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.4% 5 mg · wk 12 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.1% 5 mg · wk 12 · n 113 · Phase 3 · secondary NCT01087502
  • -0.5% vs -0.1% 5 mg · wk 8 · n 113 · Phase 3 · secondary NCT01087502
  • -0.2% vs -0.2% 5 mg · wk 6 · n 130 · Phase 3 · secondary NCT01183013
  • -0.3% vs -0.1% 5 mg · wk 4 · n 113 · Phase 3 · secondary NCT01087502
  • -0.9% vs -0.7% 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.7% 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1.3% vs -0.7% 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.7% 5 mg + 15 mg · wk 24 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.7% 5 mg + 30 mg · wk 24 · n 125 · Phase 3 · secondary NCT01183013
  • -1.2% vs -0.7% 5 mg + 45 mg · wk 24 · n 126 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.6% 5 mg + 15 mg · wk 18 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.6% 5 mg + 30 mg · wk 18 · n 125 · Phase 3 · secondary NCT01183013
  • -1.2% vs -0.6% 5 mg + 45 mg · wk 18 · n 126 · Phase 3 · secondary NCT01183013
  • -0.7% vs -0.4% 5 mg + 15 mg · wk 12 · n 120 · Phase 3 · secondary NCT01183013
  • -0.9% vs -0.4% 5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT01183013
  • -1.0% vs -0.4% 5 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT01183013
  • -0.4% vs -0.2% 5 mg + 15 mg · wk 6 · n 120 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.2% 5 mg + 30 mg · wk 6 · n 125 · Phase 3 · secondary NCT01183013
  • -0.6% vs -0.2% 5 mg + 45 mg · wk 6 · n 126 · Phase 3 · secondary NCT01183013
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 54 · n 225 · Phase 3 · secondary NCT00915772
  • -0.2% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 54 · n 171 · Phase 3 · secondary NCT00915772
  • -1.4% vs -1.2% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 54 · n 113 · Phase 3 · secondary NCT00915772
  • -1.7% vs -1.2% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 54 · n 111 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 42 · n 225 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 42 · n 171 · Phase 3 · secondary NCT00915772
  • -1.3% vs -1.2% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 42 · n 113 · Phase 3 · secondary NCT00915772
  • -1.6% vs -1.2% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 42 · n 111 · Phase 3 · secondary NCT00915772
  • -1.4% vs -1.3% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 66 · n 113 · Phase 3 · secondary NCT00915772
  • -1.6% vs -1.3% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 66 · n 111 · Phase 3 · secondary NCT00915772
  • -0.4% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 30 · n 225 · Phase 3 · secondary NCT00915772
  • -0.4% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 30 · n 171 · Phase 3 · secondary NCT00915772
  • -1.3% vs -1.2% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 30 · n 113 · Phase 3 · secondary NCT00915772
  • -1.7% vs -1.2% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 30 · n 111 · Phase 3 · secondary NCT00915772
  • -1.3% vs -1.3% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 78 · n 113 · Phase 3 · secondary NCT00915772
  • -1.6% vs -1.3% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 78 · n 111 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 18 · n 225 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 18 · n 171 · Phase 3 · secondary NCT00915772
  • -0.2% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 6 · n 225 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 6 · n 171 · Phase 3 · secondary NCT00915772
  • -1.0% vs -0.4% 5 mg · wk 24 · n 149 · Phase 4 · primary NCT02240680
  • -0.5% vs 0.3% 5 mg once daily · wk 12 · n 221 · Phase 2 · primary NCT01012037
  • -0.5% vs 0.3% 2.5 mg twice daily · wk 12 · n 214 · Phase 2 · primary NCT01012037
  • -1.0% vs -1.0% 5 mg once daily + metformin once daily · wk 14 · n 298 · Phase 4 · primary NCT01438814
  • -0.6% vs 0.3% 5 mg once daily · wk 12 · n 221 · Phase 2 · secondary NCT01012037
  • -0.3% vs 0.3% 5 mg once daily · wk 6 · n 221 · Phase 2 · secondary NCT01012037
  • -0.5% vs 0.3% 2.5 mg twice daily · wk 12 · n 214 · Phase 2 · secondary NCT01012037
  • -0.3% vs 0.3% 2.5 mg twice daily · wk 6 · n 214 · Phase 2 · secondary NCT01012037
  • -0.8% vs -0.8% 5 mg once daily + metformin once daily · wk 8 · n 298 · Phase 4 · secondary NCT01438814
  • -0.3% vs -0.3% 5 mg once daily + metformin once daily · wk 2 · n 298 · Phase 4 · secondary NCT01438814
  • 7.6% vs 8% wk 12 · n 128 · Phase 4 · secondary NCT02004366
  • 6.6% vs 8% wk 12 · n 92 · Phase 4 · secondary NCT02004366
  • 7% vs 8% wk 12 · n 93 · Phase 4 · secondary NCT02004366
  • 8.6% vs 8% wk 12 · n 39 · Phase 4 · secondary NCT02004366
-0.6% vs 0.2%−0.8 vs placebo100 mg · wk 24 · n 229NCT00087516
7 other results
  • -0.8% vs -0.1% 100 mg · wk 24 · n 163 · Phase 3 · primary NCT00086502
  • -0.8% vs 0.2% 200 mg · wk 24 · n 238 · Phase 3 · primary NCT00087516
  • -0.0% vs 0.2% wk 20 · n 95 · Phase 3 · primary NCT01485614
  • -1.1% vs -0.7% wk 20 · n 229 · Phase 3 · primary NCT02791490
  • -0.1% vs -1.0% wk 20 · n 78 · Phase 3 · primary NCT01485614
  • -0.2% vs -0.7% wk 54 · n 41 · Phase 3 · secondary NCT01485614
  • -0.5% vs -1.1% wk 26 · n 182 · Phase 4 · primary NCT01907854
Body weight, change (kg)1.4 vs -0.0+1.5 vs placebo5 mg · wk 26 · n 49NCT03429543
4 other results
  • -2.5 vs -0.3 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · secondary NCT01734785
  • -3.1 vs -0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • 2.7 vs -0.0 5 mg · wk 26 · n 6 · Phase 3 · secondary NCT03429543
  • -0.4 vs -1.1 5 mg once daily + metformin once daily · wk 14 · n 287 · Phase 4 · secondary NCT01438814
-0.5 vs -1.4vs Oral Semaglutide100 mg · wk 26 · n 335NCT04017832
1 other result
  • -1.8 vs -3.3 wk 26 · n 200 · Phase 4 · secondary NCT01907854
HbA1c below 7%26.9% vs 24.5%+2.4 vs placebo5 mg · wk 26 · n 52NCT03429543
7 other results
  • 13.9% vs 8.2% wk 24 · n 101 · Phase 3 · secondary NCT02897349
  • 16.7% vs 24.5% 5 mg · wk 26 · n 6 · Phase 3 · secondary NCT03429543
  • 43.6% vs 50% 5 mg QD · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • 72.1% vs 50% 2.5 mg / 500 mg BID · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • 77.1% vs 50% 2.5 mg / 1000 mg BID · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • 33% vs 10% 5 mg once daily · wk 12 · n 215 · Phase 2 · secondary NCT01012037
  • 34% vs 10% 2.5 mg twice daily · wk 12 · n 206 · Phase 2 · secondary NCT01012037
49.5% vs 36.8%+12.7 vs placebowk 20 · n 95NCT01485614
4 other results
  • 28.8% vs 16.6% wk 20 · n 229 · Phase 3 · secondary NCT02791490
  • 15.6% vs 5.7% wk 20 · n 122 · Phase 3 · secondary NCT02791490
  • 28.4% vs 33.3% wk 54 · n 95 · Phase 3 · secondary NCT01485614
  • 49.5% vs 77.8% wk 20 · n 95 · Phase 3 · secondary NCT01485614
Fasting plasma glucose, change-0.1 vs 0.0−0.2 vs placebo5 mg · wk 52 · n 614NCT00954447
95 other results
  • -0.4 vs -0.2 5 mg · wk 40 · n 606 · Phase 3 · secondary NCT00954447
  • -0.3 vs -0.1 5 mg · wk 32 · n 606 · Phase 3 · secondary NCT00954447
  • -0.4 vs 0.3 5 mg · wk 24 · n 614 · Phase 3 · secondary NCT00954447
  • -0.3 vs 0.2 5 mg · wk 6 · n 606 · Phase 3 · secondary NCT00954447
  • -0.3 vs 0.5 wk 24 · n 739 · Phase 3 · secondary NCT00602472
  • -0.5 vs 0.1 5 mg · wk 24 · n 196 · Phase 3 · secondary NCT01214239
  • -0.6 vs -0.1 5 mg once daily · wk 24 · n 203 · Phase 3 · secondary NCT01215097
  • -0.4 vs 0 5 mg · wk 24 · n 606 · Phase 3 · secondary NCT00954447
  • -0.2 vs 0.1 5 mg · wk 18 · n 606 · Phase 3 · secondary NCT00954447
  • -0.6 vs 0.0 5 mg tablet · wk 24 · n 175 · Phase 3 · secondary NCT00996658
  • -0.6 vs 0.6 wk 24 · n 495 · Phase 3 · secondary NCT00601250
  • -0.3 vs 0.4 wk 18 · n 739 · Phase 3 · secondary NCT00602472
  • -0.6 vs 0.6 wk 18 · n 495 · Phase 3 · secondary NCT00601250
  • -0.5 vs 0.3 wk 12 · n 739 · Phase 3 · secondary NCT00602472
  • -0.7 vs 0.2 wk 12 · n 495 · Phase 3 · secondary NCT00601250
  • -0.6 vs 0.3 wk 6 · n 739 · Phase 3 · secondary NCT00602472
  • -0.7 vs 0.3 wk 6 · n 495 · Phase 3 · secondary NCT00601250
  • -1.3 vs -0.6 5 mg · wk 24 · n 95 · Phase 3 · secondary NCT01194830
  • -0.6 vs 0.6 5 mg · wk 24 · n 156 · Phase 3 · secondary NCT01084005
  • -0.6 vs -0.1 5 mg · wk 18 · n 196 · Phase 3 · secondary NCT01214239
  • -0.7 vs -0.1 5 mg once daily · wk 18 · n 203 · Phase 3 · secondary NCT01215097
  • -0.5 vs -0.1 5 mg tablet · wk 18 · n 175 · Phase 3 · secondary NCT00996658
  • -0.7 vs 0.5 5 mg · wk 18 · n 145 · Phase 3 · secondary NCT01084005
  • -0.6 vs -0.1 5 mg · wk 12 · n 196 · Phase 3 · secondary NCT01214239
  • -0.8 vs -0.3 5 mg once daily · wk 12 · n 203 · Phase 3 · secondary NCT01215097
  • -0.4 vs -0.0 5 mg · wk 12 · n 606 · Phase 3 · secondary NCT00954447
  • -0.4 vs 0.2 5 mg tablet · wk 12 · n 175 · Phase 3 · secondary NCT00996658
  • -0.8 vs 0.4 5 mg · wk 12 · n 148 · Phase 3 · secondary NCT01084005
  • -0.7 vs -0.0 5 mg · wk 6 · n 196 · Phase 3 · secondary NCT01214239
  • -0.9 vs 0.3 5 mg once daily · wk 6 · n 203 · Phase 3 · secondary NCT01215097
  • -0.2 vs 0.7 5 mg tablet · wk 6 · n 175 · Phase 3 · secondary NCT00996658
  • -0.8 vs 0.3 5 mg · wk 6 · n 153 · Phase 3 · secondary NCT01084005
  • -1.8 vs 0.3 25 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • -1.5 vs 0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • -1.8 vs -1.0 wk 24 · n 243 · Phase 3 · secondary NCT00641043
  • -0.5 vs 0.8 wk 24 · n 318 · Phase 3 · secondary NCT00621140
  • -1.8 vs -1.1 wk 18 · n 243 · Phase 3 · secondary NCT00641043
  • -0.4 vs 0.7 wk 18 · n 318 · Phase 3 · secondary NCT00621140
  • -1.9 vs -1.1 wk 12 · n 243 · Phase 3 · secondary NCT00641043
  • -0.6 vs 0.6 wk 12 · n 318 · Phase 3 · secondary NCT00621140
  • -1.9 vs -0.9 wk 6 · n 243 · Phase 3 · secondary NCT00641043
  • -0.6 vs 0.4 wk 6 · n 318 · Phase 3 · secondary NCT00621140
  • 0.2 vs -0.2 5 mg · wk 52 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -0.1 5 mg · wk 46 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -0.0 5 mg · wk 40 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -0.6 5 mg · wk 34 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -1.6 5 mg · wk 30 · n 130 · Phase 3 · secondary NCT01183013
  • 0 vs -1.4 5 mg · wk 30 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5 vs -0.5 5 mg · wk 28 · n 112 · Phase 3 · secondary NCT01087502
  • -0.8 vs -1.7 5 mg QD · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • -0.3 vs -1.2 5 mg · wk 24 · n 130 · Phase 3 · secondary NCT01183013
  • -0.7 vs -0.5 5 mg · wk 24 · n 112 · Phase 3 · secondary NCT01087502
  • -0.3 vs -0.5 5 mg · wk 20 · n 112 · Phase 3 · secondary NCT01087502
  • -0.4 vs -1.1 5 mg · wk 18 · n 130 · Phase 3 · secondary NCT01183013
  • -0.4 vs -1.2 5 mg · wk 12 · n 130 · Phase 3 · secondary NCT01183013
  • 0.0 vs 0.5 5 mg · wk 12 · n 112 · Phase 3 · secondary NCT01087502
  • -0.3 vs 0.3 5 mg · wk 12 · n 112 · Phase 3 · secondary NCT01087502
  • -0.6 vs 0.5 5 mg · wk 8 · n 112 · Phase 3 · secondary NCT01087502
  • -0.2 vs -0.9 5 mg · wk 6 · n 130 · Phase 3 · secondary NCT01183013
  • -0.6 vs 0.5 5 mg · wk 4 · n 112 · Phase 3 · secondary NCT01087502
  • -1.1 vs -1.6 5 mg + 15 mg · wk 30 · n 119 · Phase 3 · secondary NCT01183013
  • -1.5 vs -1.6 5 mg + 30 mg · wk 30 · n 123 · Phase 3 · secondary NCT01183013
  • -1.9 vs -1.6 5 mg + 45 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1 vs -1.4 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · secondary NCT01183013
  • -1.5 vs -1.4 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1.9 vs -1.4 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · secondary NCT01183013
  • -0.9 vs -1.2 5 mg + 15 mg · wk 24 · n 120 · Phase 3 · secondary NCT01183013
  • -1.8 vs -1.2 5 mg + 30 mg · wk 24 · n 125 · Phase 3 · secondary NCT01183013
  • -1.8 vs -1.2 5 mg + 45 mg · wk 24 · n 126 · Phase 3 · secondary NCT01183013
  • -1.1 vs -1.1 5 mg + 15 mg · wk 18 · n 120 · Phase 3 · secondary NCT01183013
  • -1.7 vs -1.1 5 mg + 30 mg · wk 18 · n 125 · Phase 3 · secondary NCT01183013
  • -1.7 vs -1.1 5 mg + 45 mg · wk 18 · n 126 · Phase 3 · secondary NCT01183013
  • -1 vs -1.2 5 mg + 15 mg · wk 12 · n 120 · Phase 3 · secondary NCT01183013
  • -1.7 vs -1.2 5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT01183013
  • -1.6 vs -1.2 5 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT01183013
  • -1.1 vs -0.9 5 mg + 15 mg · wk 6 · n 120 · Phase 3 · secondary NCT01183013
  • -1.5 vs -0.9 5 mg + 30 mg · wk 6 · n 125 · Phase 3 · secondary NCT01183013
  • -1.6 vs -0.9 5 mg + 45 mg · wk 6 · n 126 · Phase 3 · secondary NCT01183013
  • -0.4 vs -0.3 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 54 · n 225 · Phase 3 · secondary NCT00915772
  • -0.6 vs -0.3 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 54 · n 171 · Phase 3 · secondary NCT00915772
  • -0.5 vs -0.4 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 42 · n 225 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.4 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 42 · n 171 · Phase 3 · secondary NCT00915772
  • -0.8 vs -0.4 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 30 · n 225 · Phase 3 · secondary NCT00915772
  • -0.8 vs -0.4 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 30 · n 171 · Phase 3 · secondary NCT00915772
  • -2.2 vs -1.7 2.5 mg / 500 mg BID · wk 24 · n 142 · Phase 3 · secondary NCT01708902
  • -2.6 vs -1.7 2.5 mg / 1000 mg BID · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • -0.7 vs -0.1 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 18 · n 225 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.1 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 18 · n 171 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.2 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 6 · n 225 · Phase 3 · secondary NCT00915772
  • -0.8 vs -0.2 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 6 · n 171 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.2 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 2 · n 225 · Phase 3 · secondary NCT00915772
  • -0.6 vs -0.2 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 2 · n 171 · Phase 3 · secondary NCT00915772
  • -1.2 vs -0.2 5 mg once daily · wk 12 · n 213 · Phase 2 · secondary NCT01012037
  • -0.9 vs -0.2 2.5 mg twice daily · wk 12 · n 203 · Phase 2 · secondary NCT01012037
  • -1.4 vs -1.5 5 mg once daily + metformin once daily · wk 14 · n 298 · Phase 4 · secondary NCT01438814
-0.7 vs 0.3−0.9 vs placebo100 mg · wk 24 · n 234NCT00087516
7 other results
  • -0.9 vs 0.1 100 mg · wk 24 · n 163 · Phase 3 · secondary NCT00086502
  • -0.9 vs 0.3 200 mg · wk 24 · n 244 · Phase 3 · secondary NCT00087516
  • 0.4 vs 0.3 wk 20 · n 95 · Phase 3 · secondary NCT01485614
  • -1.6 vs -0.9 wk 20 · n 229 · Phase 3 · secondary NCT02791490
  • -0.5 vs -1.0 100 mg · wk 26 · n 329 · Phase 3 · secondary NCT04017832
  • -0.2 vs -1.7 wk 54 · n 44 · Phase 3 · secondary NCT01485614
  • 0.6 vs -1.1 wk 20 · n 81 · Phase 3 · secondary NCT01485614
3-point MACE (% with event)20.7% vs 21.2%vs Glimepiridewk 432 · n 3023NCT01243424
2 other results
  • 11.8% vs 12% wk 432 · n 3023 · Phase 3 · secondary NCT01243424
  • 12.4% vs 12.1% n 3494 · Phase 4 · primary NCT01897532
—Not posted · NCT01529541

HbA1c, change

Linagliptin
-0.6% vs 0.1%−0.6 vs placebo5 mg · wk 24 · n 618NCT00954447
129 other results
  • -0.7% vs -0.1% wk 24 · n 778 · Phase 3 · primary NCT00602472
  • -0.5% vs 0.1% wk 24 · n 513 · Phase 3 · primary NCT00601250
  • -0.6% vs -0.0% 5 mg · wk 24 · n 161 · Phase 3 · primary NCT01792518
  • -0.7% vs -0.2% 5 mg · wk 24 · n 196 · Phase 3 · primary NCT01214239
  • -0.7% vs -0.1% 5 mg once daily · wk 24 · n 203 · Phase 3 · primary NCT01215097
  • -0.8% vs -0.3% 5 mg tablet · wk 24 · n 179 · Phase 3 · primary NCT00996658
  • -0.8% vs -0.3% 5 mg · wk 24 · n 93 · Phase 3 · primary NCT01194830
  • -0.6% vs 0.0% 5 mg · wk 24 · n 160 · Phase 3 · primary NCT01084005
  • -0.5% vs -0.1% 5 mg · wk 12 · n 113 · Phase 3 · primary NCT01087502
  • -1.1% vs -0.6% wk 24 · n 252 · Phase 3 · primary NCT00641043
  • -0.4% vs 0.3% wk 24 · n 333 · Phase 3 · primary NCT00621140
  • -0.9% vs -0.3% 25 mg + 5 mg · wk 24 · n 111 · Phase 3 · primary NCT02489968
  • -0.6% vs 0.1% 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · primary NCT01734785
  • -0.9% vs -0.3% 10 mg + 5 mg · wk 24 · n 103 · Phase 3 · primary NCT02489968
  • -0.7% vs 0.1% 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · primary NCT01734785
  • -0.6% vs -0.2% wk 24 · n 100 · Phase 3 · primary NCT02897349
  • -0.4% vs -0.7% 5 mg · wk 30 · n 130 · Phase 3 · primary NCT01183013
  • 0.3% vs -0.2% 5 mg · wk 26 · n 52 · Phase 3 · primary NCT03429543
  • -1.3% vs -1.6% 5 mg QD · wk 24 · n 141 · Phase 3 · primary NCT01708902
  • -1.3% vs -1.7% 5 mg QD · wk 24 · n 125 · Phase 3 · primary NCT01708902
  • -0.8% vs -0.7% 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · primary NCT01183013
  • -1.1% vs -0.7% 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · primary NCT01183013
  • -1.3% vs -0.7% 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · primary NCT01183013
  • -2.1% vs -1.6% 2.5 mg / 500 mg BID · wk 24 · n 142 · Phase 3 · primary NCT01708902
  • -2.3% vs -1.6% 2.5 mg / 1000 mg BID · wk 24 · n 141 · Phase 3 · primary NCT01708902
  • -2.2% vs -1.7% 2.5 mg / 500 mg BID · wk 24 · n 135 · Phase 3 · primary NCT01708902
  • -2.4% vs -1.7% 2.5 mg / 1000 mg BID · wk 24 · n 128 · Phase 3 · primary NCT01708902
  • -0.5% vs 0.1% 5 mg · wk 52 · n 618 · Phase 3 · secondary NCT00954447
  • -0.5% vs 0.1% 5 mg · wk 40 · n 618 · Phase 3 · secondary NCT00954447
  • -0.6% vs 0.0% 5 mg · wk 32 · n 618 · Phase 3 · secondary NCT00954447
  • -0.6% vs 0.0% 5 mg · wk 18 · n 618 · Phase 3 · secondary NCT00954447
  • -0.6% vs 0.0% 5 mg · wk 12 · n 618 · Phase 3 · secondary NCT00954447
  • -0.5% vs 0% 5 mg · wk 6 · n 618 · Phase 3 · secondary NCT00954447
  • -0.8% vs -0.1% wk 18 · n 778 · Phase 3 · secondary NCT00602472
  • -0.7% vs -0.2% 5 mg · wk 24 · n 168 · Phase 3 · secondary NCT01214239
  • -0.7% vs -0.2% 5 mg once daily · wk 24 · n 182 · Phase 3 · secondary NCT01215097
  • -0.7% vs -0.2% 5 mg · wk 18 · n 196 · Phase 3 · secondary NCT01214239
  • -0.6% vs -0.1% 5 mg once daily · wk 18 · n 203 · Phase 3 · secondary NCT01215097
  • -0.9% vs -0.4% 5 mg tablet · wk 18 · n 179 · Phase 3 · secondary NCT00996658
  • -0.8% vs -0.3% 5 mg · wk 18 · n 93 · Phase 3 · secondary NCT01194830
  • -0.6% vs 0.0% 5 mg · wk 18 · n 160 · Phase 3 · secondary NCT01084005
  • -0.6% vs -0.1% 5 mg · wk 12 · n 196 · Phase 3 · secondary NCT01214239
  • -0.7% vs -0.1% 5 mg once daily · wk 12 · n 203 · Phase 3 · secondary NCT01215097
  • -0.8% vs -0.3% 5 mg tablet · wk 12 · n 179 · Phase 3 · secondary NCT00996658
  • -0.7% vs -0.2% 5 mg · wk 12 · n 93 · Phase 3 · secondary NCT01194830
  • -0.6% vs -0.0% 5 mg · wk 12 · n 160 · Phase 3 · secondary NCT01084005
  • -0.5% vs -0.1% 5 mg · wk 6 · n 196 · Phase 3 · secondary NCT01214239
  • -0.5% vs -0.0% 5 mg once daily · wk 6 · n 203 · Phase 3 · secondary NCT01215097
  • -0.6% vs -0.2% 5 mg tablet · wk 6 · n 179 · Phase 3 · secondary NCT00996658
  • -0.5% vs 0.1% wk 18 · n 513 · Phase 3 · secondary NCT00601250
  • -0.4% vs -0.1% 5 mg · wk 6 · n 160 · Phase 3 · secondary NCT01084005
  • -1.1% vs -0.6% wk 18 · n 252 · Phase 3 · secondary NCT00641043
  • -0.5% vs 0.2% wk 18 · n 333 · Phase 3 · secondary NCT00621140
  • -0.8% vs -0.1% wk 12 · n 778 · Phase 3 · secondary NCT00602472
  • -0.5% vs 0.1% wk 12 · n 513 · Phase 3 · secondary NCT00601250
  • -0.8% vs -0.3% wk 12 · n 252 · Phase 3 · secondary NCT00641043
  • -0.5% vs 0.2% wk 12 · n 333 · Phase 3 · secondary NCT00621140
  • -0.7% vs -0.2% wk 6 · n 778 · Phase 3 · secondary NCT00602472
  • -0.4% vs 0.1% wk 6 · n 513 · Phase 3 · secondary NCT00601250
  • -0.4% vs -0.0% wk 6 · n 252 · Phase 3 · secondary NCT00641043
  • -0.4% vs 0.1% wk 6 · n 333 · Phase 3 · secondary NCT00621140
  • -0.6% vs -0.2% 5 mg · wk 6 · n 93 · Phase 3 · secondary NCT01194830
  • -0.5% vs 0.1% 5 mg · wk 26 · n 5 · Phase 3 · secondary NCT03429543
  • 0.1% vs 0.1% wk 432 · n 2951 · Phase 3 · secondary NCT01243424
  • -0.4% vs -0.3% 5 mg · wk 52 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.2% 5 mg · wk 46 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.2% 5 mg · wk 40 · n 113 · Phase 3 · secondary NCT01087502
  • -0.5% vs -0.4% 5 mg · wk 34 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.7% 5 mg · wk 30 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.5% 5 mg · wk 28 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.7% 5 mg · wk 24 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.5% 5 mg · wk 24 · n 113 · Phase 3 · secondary NCT01087502
  • -0.5% vs -0.5% 5 mg · wk 20 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.6% 5 mg · wk 18 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.3% 5 mg · wk 16 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.4% 5 mg · wk 12 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.1% 5 mg · wk 12 · n 113 · Phase 3 · secondary NCT01087502
  • -0.5% vs -0.1% 5 mg · wk 8 · n 113 · Phase 3 · secondary NCT01087502
  • -0.2% vs -0.2% 5 mg · wk 6 · n 130 · Phase 3 · secondary NCT01183013
  • -0.3% vs -0.1% 5 mg · wk 4 · n 113 · Phase 3 · secondary NCT01087502
  • -0.9% vs -0.7% 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.7% 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1.3% vs -0.7% 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.7% 5 mg + 15 mg · wk 24 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.7% 5 mg + 30 mg · wk 24 · n 125 · Phase 3 · secondary NCT01183013
  • -1.2% vs -0.7% 5 mg + 45 mg · wk 24 · n 126 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.6% 5 mg + 15 mg · wk 18 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.6% 5 mg + 30 mg · wk 18 · n 125 · Phase 3 · secondary NCT01183013
  • -1.2% vs -0.6% 5 mg + 45 mg · wk 18 · n 126 · Phase 3 · secondary NCT01183013
  • -0.7% vs -0.4% 5 mg + 15 mg · wk 12 · n 120 · Phase 3 · secondary NCT01183013
  • -0.9% vs -0.4% 5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT01183013
  • -1.0% vs -0.4% 5 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT01183013
  • -0.4% vs -0.2% 5 mg + 15 mg · wk 6 · n 120 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.2% 5 mg + 30 mg · wk 6 · n 125 · Phase 3 · secondary NCT01183013
  • -0.6% vs -0.2% 5 mg + 45 mg · wk 6 · n 126 · Phase 3 · secondary NCT01183013
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 54 · n 225 · Phase 3 · secondary NCT00915772
  • -0.2% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 54 · n 171 · Phase 3 · secondary NCT00915772
  • -1.4% vs -1.2% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 54 · n 113 · Phase 3 · secondary NCT00915772
  • -1.7% vs -1.2% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 54 · n 111 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 42 · n 225 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 42 · n 171 · Phase 3 · secondary NCT00915772
  • -1.3% vs -1.2% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 42 · n 113 · Phase 3 · secondary NCT00915772
  • -1.6% vs -1.2% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 42 · n 111 · Phase 3 · secondary NCT00915772
  • -1.4% vs -1.3% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 66 · n 113 · Phase 3 · secondary NCT00915772
  • -1.6% vs -1.3% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 66 · n 111 · Phase 3 · secondary NCT00915772
  • -0.4% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 30 · n 225 · Phase 3 · secondary NCT00915772
  • -0.4% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 30 · n 171 · Phase 3 · secondary NCT00915772
  • -1.3% vs -1.2% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 30 · n 113 · Phase 3 · secondary NCT00915772
  • -1.7% vs -1.2% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 30 · n 111 · Phase 3 · secondary NCT00915772
  • -1.3% vs -1.3% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 78 · n 113 · Phase 3 · secondary NCT00915772
  • -1.6% vs -1.3% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 78 · n 111 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 18 · n 225 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 18 · n 171 · Phase 3 · secondary NCT00915772
  • -0.2% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 6 · n 225 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 6 · n 171 · Phase 3 · secondary NCT00915772
  • -1.0% vs -0.4% 5 mg · wk 24 · n 149 · Phase 4 · primary NCT02240680
  • -0.5% vs 0.3% 5 mg once daily · wk 12 · n 221 · Phase 2 · primary NCT01012037
  • -0.5% vs 0.3% 2.5 mg twice daily · wk 12 · n 214 · Phase 2 · primary NCT01012037
  • -1.0% vs -1.0% 5 mg once daily + metformin once daily · wk 14 · n 298 · Phase 4 · primary NCT01438814
  • -0.6% vs 0.3% 5 mg once daily · wk 12 · n 221 · Phase 2 · secondary NCT01012037
  • -0.3% vs 0.3% 5 mg once daily · wk 6 · n 221 · Phase 2 · secondary NCT01012037
  • -0.5% vs 0.3% 2.5 mg twice daily · wk 12 · n 214 · Phase 2 · secondary NCT01012037
  • -0.3% vs 0.3% 2.5 mg twice daily · wk 6 · n 214 · Phase 2 · secondary NCT01012037
  • -0.8% vs -0.8% 5 mg once daily + metformin once daily · wk 8 · n 298 · Phase 4 · secondary NCT01438814
  • -0.3% vs -0.3% 5 mg once daily + metformin once daily · wk 2 · n 298 · Phase 4 · secondary NCT01438814
  • 7.6% vs 8% wk 12 · n 128 · Phase 4 · secondary NCT02004366
  • 6.6% vs 8% wk 12 · n 92 · Phase 4 · secondary NCT02004366
  • 7% vs 8% wk 12 · n 93 · Phase 4 · secondary NCT02004366
  • 8.6% vs 8% wk 12 · n 39 · Phase 4 · secondary NCT02004366
Sitagliptin
-0.6% vs 0.2%−0.8 vs placebo100 mg · wk 24 · n 229NCT00087516
7 other results
  • -0.8% vs -0.1% 100 mg · wk 24 · n 163 · Phase 3 · primary NCT00086502
  • -0.8% vs 0.2% 200 mg · wk 24 · n 238 · Phase 3 · primary NCT00087516
  • -0.0% vs 0.2% wk 20 · n 95 · Phase 3 · primary NCT01485614
  • -1.1% vs -0.7% wk 20 · n 229 · Phase 3 · primary NCT02791490
  • -0.1% vs -1.0% wk 20 · n 78 · Phase 3 · primary NCT01485614
  • -0.2% vs -0.7% wk 54 · n 41 · Phase 3 · secondary NCT01485614
  • -0.5% vs -1.1% wk 26 · n 182 · Phase 4 · primary NCT01907854

Body weight, change (kg)

Linagliptin
1.4 vs -0.0+1.5 vs placebo5 mg · wk 26 · n 49NCT03429543
4 other results
  • -2.5 vs -0.3 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · secondary NCT01734785
  • -3.1 vs -0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • 2.7 vs -0.0 5 mg · wk 26 · n 6 · Phase 3 · secondary NCT03429543
  • -0.4 vs -1.1 5 mg once daily + metformin once daily · wk 14 · n 287 · Phase 4 · secondary NCT01438814
Sitagliptin
-0.5 vs -1.4vs Oral Semaglutide100 mg · wk 26 · n 335NCT04017832
1 other result
  • -1.8 vs -3.3 wk 26 · n 200 · Phase 4 · secondary NCT01907854

HbA1c below 7%

Linagliptin
26.9% vs 24.5%+2.4 vs placebo5 mg · wk 26 · n 52NCT03429543
7 other results
  • 13.9% vs 8.2% wk 24 · n 101 · Phase 3 · secondary NCT02897349
  • 16.7% vs 24.5% 5 mg · wk 26 · n 6 · Phase 3 · secondary NCT03429543
  • 43.6% vs 50% 5 mg QD · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • 72.1% vs 50% 2.5 mg / 500 mg BID · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • 77.1% vs 50% 2.5 mg / 1000 mg BID · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • 33% vs 10% 5 mg once daily · wk 12 · n 215 · Phase 2 · secondary NCT01012037
  • 34% vs 10% 2.5 mg twice daily · wk 12 · n 206 · Phase 2 · secondary NCT01012037
Sitagliptin
49.5% vs 36.8%+12.7 vs placebowk 20 · n 95NCT01485614
4 other results
  • 28.8% vs 16.6% wk 20 · n 229 · Phase 3 · secondary NCT02791490
  • 15.6% vs 5.7% wk 20 · n 122 · Phase 3 · secondary NCT02791490
  • 28.4% vs 33.3% wk 54 · n 95 · Phase 3 · secondary NCT01485614
  • 49.5% vs 77.8% wk 20 · n 95 · Phase 3 · secondary NCT01485614

Fasting plasma glucose, change

Linagliptin
-0.1 vs 0.0−0.2 vs placebo5 mg · wk 52 · n 614NCT00954447
95 other results
  • -0.4 vs -0.2 5 mg · wk 40 · n 606 · Phase 3 · secondary NCT00954447
  • -0.3 vs -0.1 5 mg · wk 32 · n 606 · Phase 3 · secondary NCT00954447
  • -0.4 vs 0.3 5 mg · wk 24 · n 614 · Phase 3 · secondary NCT00954447
  • -0.3 vs 0.2 5 mg · wk 6 · n 606 · Phase 3 · secondary NCT00954447
  • -0.3 vs 0.5 wk 24 · n 739 · Phase 3 · secondary NCT00602472
  • -0.5 vs 0.1 5 mg · wk 24 · n 196 · Phase 3 · secondary NCT01214239
  • -0.6 vs -0.1 5 mg once daily · wk 24 · n 203 · Phase 3 · secondary NCT01215097
  • -0.4 vs 0 5 mg · wk 24 · n 606 · Phase 3 · secondary NCT00954447
  • -0.2 vs 0.1 5 mg · wk 18 · n 606 · Phase 3 · secondary NCT00954447
  • -0.6 vs 0.0 5 mg tablet · wk 24 · n 175 · Phase 3 · secondary NCT00996658
  • -0.6 vs 0.6 wk 24 · n 495 · Phase 3 · secondary NCT00601250
  • -0.3 vs 0.4 wk 18 · n 739 · Phase 3 · secondary NCT00602472
  • -0.6 vs 0.6 wk 18 · n 495 · Phase 3 · secondary NCT00601250
  • -0.5 vs 0.3 wk 12 · n 739 · Phase 3 · secondary NCT00602472
  • -0.7 vs 0.2 wk 12 · n 495 · Phase 3 · secondary NCT00601250
  • -0.6 vs 0.3 wk 6 · n 739 · Phase 3 · secondary NCT00602472
  • -0.7 vs 0.3 wk 6 · n 495 · Phase 3 · secondary NCT00601250
  • -1.3 vs -0.6 5 mg · wk 24 · n 95 · Phase 3 · secondary NCT01194830
  • -0.6 vs 0.6 5 mg · wk 24 · n 156 · Phase 3 · secondary NCT01084005
  • -0.6 vs -0.1 5 mg · wk 18 · n 196 · Phase 3 · secondary NCT01214239
  • -0.7 vs -0.1 5 mg once daily · wk 18 · n 203 · Phase 3 · secondary NCT01215097
  • -0.5 vs -0.1 5 mg tablet · wk 18 · n 175 · Phase 3 · secondary NCT00996658
  • -0.7 vs 0.5 5 mg · wk 18 · n 145 · Phase 3 · secondary NCT01084005
  • -0.6 vs -0.1 5 mg · wk 12 · n 196 · Phase 3 · secondary NCT01214239
  • -0.8 vs -0.3 5 mg once daily · wk 12 · n 203 · Phase 3 · secondary NCT01215097
  • -0.4 vs -0.0 5 mg · wk 12 · n 606 · Phase 3 · secondary NCT00954447
  • -0.4 vs 0.2 5 mg tablet · wk 12 · n 175 · Phase 3 · secondary NCT00996658
  • -0.8 vs 0.4 5 mg · wk 12 · n 148 · Phase 3 · secondary NCT01084005
  • -0.7 vs -0.0 5 mg · wk 6 · n 196 · Phase 3 · secondary NCT01214239
  • -0.9 vs 0.3 5 mg once daily · wk 6 · n 203 · Phase 3 · secondary NCT01215097
  • -0.2 vs 0.7 5 mg tablet · wk 6 · n 175 · Phase 3 · secondary NCT00996658
  • -0.8 vs 0.3 5 mg · wk 6 · n 153 · Phase 3 · secondary NCT01084005
  • -1.8 vs 0.3 25 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • -1.5 vs 0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • -1.8 vs -1.0 wk 24 · n 243 · Phase 3 · secondary NCT00641043
  • -0.5 vs 0.8 wk 24 · n 318 · Phase 3 · secondary NCT00621140
  • -1.8 vs -1.1 wk 18 · n 243 · Phase 3 · secondary NCT00641043
  • -0.4 vs 0.7 wk 18 · n 318 · Phase 3 · secondary NCT00621140
  • -1.9 vs -1.1 wk 12 · n 243 · Phase 3 · secondary NCT00641043
  • -0.6 vs 0.6 wk 12 · n 318 · Phase 3 · secondary NCT00621140
  • -1.9 vs -0.9 wk 6 · n 243 · Phase 3 · secondary NCT00641043
  • -0.6 vs 0.4 wk 6 · n 318 · Phase 3 · secondary NCT00621140
  • 0.2 vs -0.2 5 mg · wk 52 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -0.1 5 mg · wk 46 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -0.0 5 mg · wk 40 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -0.6 5 mg · wk 34 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -1.6 5 mg · wk 30 · n 130 · Phase 3 · secondary NCT01183013
  • 0 vs -1.4 5 mg · wk 30 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5 vs -0.5 5 mg · wk 28 · n 112 · Phase 3 · secondary NCT01087502
  • -0.8 vs -1.7 5 mg QD · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • -0.3 vs -1.2 5 mg · wk 24 · n 130 · Phase 3 · secondary NCT01183013
  • -0.7 vs -0.5 5 mg · wk 24 · n 112 · Phase 3 · secondary NCT01087502
  • -0.3 vs -0.5 5 mg · wk 20 · n 112 · Phase 3 · secondary NCT01087502
  • -0.4 vs -1.1 5 mg · wk 18 · n 130 · Phase 3 · secondary NCT01183013
  • -0.4 vs -1.2 5 mg · wk 12 · n 130 · Phase 3 · secondary NCT01183013
  • 0.0 vs 0.5 5 mg · wk 12 · n 112 · Phase 3 · secondary NCT01087502
  • -0.3 vs 0.3 5 mg · wk 12 · n 112 · Phase 3 · secondary NCT01087502
  • -0.6 vs 0.5 5 mg · wk 8 · n 112 · Phase 3 · secondary NCT01087502
  • -0.2 vs -0.9 5 mg · wk 6 · n 130 · Phase 3 · secondary NCT01183013
  • -0.6 vs 0.5 5 mg · wk 4 · n 112 · Phase 3 · secondary NCT01087502
  • -1.1 vs -1.6 5 mg + 15 mg · wk 30 · n 119 · Phase 3 · secondary NCT01183013
  • -1.5 vs -1.6 5 mg + 30 mg · wk 30 · n 123 · Phase 3 · secondary NCT01183013
  • -1.9 vs -1.6 5 mg + 45 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1 vs -1.4 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · secondary NCT01183013
  • -1.5 vs -1.4 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1.9 vs -1.4 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · secondary NCT01183013
  • -0.9 vs -1.2 5 mg + 15 mg · wk 24 · n 120 · Phase 3 · secondary NCT01183013
  • -1.8 vs -1.2 5 mg + 30 mg · wk 24 · n 125 · Phase 3 · secondary NCT01183013
  • -1.8 vs -1.2 5 mg + 45 mg · wk 24 · n 126 · Phase 3 · secondary NCT01183013
  • -1.1 vs -1.1 5 mg + 15 mg · wk 18 · n 120 · Phase 3 · secondary NCT01183013
  • -1.7 vs -1.1 5 mg + 30 mg · wk 18 · n 125 · Phase 3 · secondary NCT01183013
  • -1.7 vs -1.1 5 mg + 45 mg · wk 18 · n 126 · Phase 3 · secondary NCT01183013
  • -1 vs -1.2 5 mg + 15 mg · wk 12 · n 120 · Phase 3 · secondary NCT01183013
  • -1.7 vs -1.2 5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT01183013
  • -1.6 vs -1.2 5 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT01183013
  • -1.1 vs -0.9 5 mg + 15 mg · wk 6 · n 120 · Phase 3 · secondary NCT01183013
  • -1.5 vs -0.9 5 mg + 30 mg · wk 6 · n 125 · Phase 3 · secondary NCT01183013
  • -1.6 vs -0.9 5 mg + 45 mg · wk 6 · n 126 · Phase 3 · secondary NCT01183013
  • -0.4 vs -0.3 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 54 · n 225 · Phase 3 · secondary NCT00915772
  • -0.6 vs -0.3 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 54 · n 171 · Phase 3 · secondary NCT00915772
  • -0.5 vs -0.4 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 42 · n 225 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.4 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 42 · n 171 · Phase 3 · secondary NCT00915772
  • -0.8 vs -0.4 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 30 · n 225 · Phase 3 · secondary NCT00915772
  • -0.8 vs -0.4 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 30 · n 171 · Phase 3 · secondary NCT00915772
  • -2.2 vs -1.7 2.5 mg / 500 mg BID · wk 24 · n 142 · Phase 3 · secondary NCT01708902
  • -2.6 vs -1.7 2.5 mg / 1000 mg BID · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • -0.7 vs -0.1 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 18 · n 225 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.1 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 18 · n 171 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.2 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 6 · n 225 · Phase 3 · secondary NCT00915772
  • -0.8 vs -0.2 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 6 · n 171 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.2 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 2 · n 225 · Phase 3 · secondary NCT00915772
  • -0.6 vs -0.2 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 2 · n 171 · Phase 3 · secondary NCT00915772
  • -1.2 vs -0.2 5 mg once daily · wk 12 · n 213 · Phase 2 · secondary NCT01012037
  • -0.9 vs -0.2 2.5 mg twice daily · wk 12 · n 203 · Phase 2 · secondary NCT01012037
  • -1.4 vs -1.5 5 mg once daily + metformin once daily · wk 14 · n 298 · Phase 4 · secondary NCT01438814
Sitagliptin
-0.7 vs 0.3−0.9 vs placebo100 mg · wk 24 · n 234NCT00087516
7 other results
  • -0.9 vs 0.1 100 mg · wk 24 · n 163 · Phase 3 · secondary NCT00086502
  • -0.9 vs 0.3 200 mg · wk 24 · n 244 · Phase 3 · secondary NCT00087516
  • 0.4 vs 0.3 wk 20 · n 95 · Phase 3 · secondary NCT01485614
  • -1.6 vs -0.9 wk 20 · n 229 · Phase 3 · secondary NCT02791490
  • -0.5 vs -1.0 100 mg · wk 26 · n 329 · Phase 3 · secondary NCT04017832
  • -0.2 vs -1.7 wk 54 · n 44 · Phase 3 · secondary NCT01485614
  • 0.6 vs -1.1 wk 20 · n 81 · Phase 3 · secondary NCT01485614

3-point MACE (% with event)

Linagliptin
20.7% vs 21.2%vs Glimepiridewk 432 · n 3023NCT01243424
2 other results
  • 11.8% vs 12% wk 432 · n 3023 · Phase 3 · secondary NCT01243424
  • 12.4% vs 12.1% n 3494 · Phase 4 · primary NCT01897532
Sitagliptin
—Not posted · NCT01529541
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
9 other shared endpoints and safety

Coverage. Linagliptin: 13 of 13 rows · Sitagliptin: 13 of 13 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLinagliptin
Rows use multiple source trials
Sitagliptin
Rows use multiple source trials
Fasting Plasma Glucose
absolute change · mmol/L
No placebo or comparator arm
-1.68 mmol/L @ 24wk*5 mga,b
NCT01512979 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -30.2 mg/dL as posted
show 3 more doses
-1.67 mmol/L @ 24wk*5 mg
NCT01512979 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -30.1 mg/dL as posted
-2.61 mmol/L @ 24wk*5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -47.1 mg/dL as posted
-2.61 mmol/L @ 24wk*5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -47.1 mg/dL as posted
-1.9 mmol/L @ 24wka,b
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
show 2 more doses
-2.03 mmol/L @ 24wk
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
-1.96 mmol/L @ 24wk
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
Fasting Plasma Glucose mg/dL
absolute value · mmol/L
6.1 vs 7.2 placebo mmol/L @ 12wk*b,c
NCT02467478 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 109.93 mg/dL as posted
4 other source trials
8.88 vs 9.27 Basal Bolus mmol/L*
NCT02004366 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 160 mg/dL as posted
6.94 vs 9.27 Basal Bolus mmol/L*
NCT02004366 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 125 mg/dL as posted
7.38 vs 9.27 Basal Bolus mmol/L*
NCT02004366 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from 133 mg/dL as posted
7.83 vs 9.27 Basal Bolus mmol/L*
NCT02004366 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from 141 mg/dL as posted
8.33 vs 8.88 placebo mmol/L @ 6wk*a,b,c
NCT00820573 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 150 mg/dL as posted
show 1 more dose
6.66 vs 8.88 placebo mmol/L @ 6wk*
NCT00820573 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from 120 mg/dL as posted
Glycemic Rescue
responder rate · % of participants
7.1% (n=141) vs 2.1% (n=144) Metformin @ 24wk5 mg QDa,b,d
NCT01708902 · Phase 3 · registry result, not featured evidence
show 2 more doses
2.1% (n=141) vs 2.1% (n=144) Metformin @ 24wk2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
1.4% (n=142) vs 2.1% (n=144) Metformin @ 24wk2.5 mg / 500 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
35.8% (n=95) vs 11.1% (n=9) Metformin @ 54wkb,d
NCT01485614 · Phase 3 · registry result, not featured evidence
HbA1c
absolute change · percentage points
No placebo or comparator arm
-2.02% (n=113) @ 24wk5 mga,b
NCT01512979 · Phase 4 · registry result, not featured evidence
show 3 more doses
-2.01% (n=113) @ 24wk5 mg
NCT01512979 · Phase 4 · registry result, not featured evidence
-2.81% (n=132) @ 24wk5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination
-2.81% (n=132) @ 24wk5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination
-1.27% (n=183) @ 24wka,b
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
show 2 more doses
-1.51% (n=189) @ 24wk
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
-1.15% (n=187) @ 24wk
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
HbA1c Less Than 6 5
responder rate · % of participants
15.4% (n=52) vs 9.4% (n=53) placebo @ 26wk5 mga,b,e,f
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more dose
16.7% (n=6) vs 9.4% (n=53) placebo @ 26wk5 mg
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
20% (n=95) vs 22.2% (n=9) Metformin @ 54wkb,e,f
NCT01485614 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7
absolute value · percentage points
22.1% (n=108) vs 11.8% (n=110) Glimepiride @ 52wk5 mgg,h,b,e,i
NCT01087502 · Phase 3 · registry result, not featured evidence
26.9% (n=182) vs 50.6% (n=176) Liraglutide @ 26wkg,h,b,e,i
Yes
NCT01907854 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7%
event count · % of participants
39.2% (n=171) vs 30% (n=170) metformin @ 54wk*linagliptin 2.5 mg bid + metformin 1000 mg bida,b,e,j
NCT00915772 · Phase 3 · registry result, not featured evidence · combination · converted to % from 67 participant as posted
show 1 more dose
25.3% (n=225) vs 30% (n=170) metformin @ 54wk*linagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination · converted to % from 57 participant as posted
36.5% (n=334) vs 43.3% (n=321) Oral Semaglutide @ 26wk*100 mgb,e,j
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 122 Participants as posted
HbA1c Less Than 7%
responder rate · % of participants
No placebo or comparator arm
27.1% (n=70) @ 12wk5 mg QDa,h,b,k
NCT01708902 · Phase 3 · registry result, not featured evidence
show 1 more dose
58.8% (n=68) @ 12wk2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
26.6% (n=94) @ 20wka,h,b,k
NCT00870194 · Phase 4 · registry result, not featured evidence
show 1 more dose
41.7% (n=108) @ 20wk
NCT00870194 · Phase 4 · registry result, not featured evidence · combination
PPG 2h Change mg/dL
absolute change · mmol/L
-2.86 vs -1.7 pioglitazone mmol/L @ 30wk*5 mga,h,b,l
NCT01183013 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -51.61 mg/dL as posted
show 3 more doses
-3.73 vs -1.7 pioglitazone mmol/L @ 30wk*5 mg + 15 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -67.26 mg/dL as posted
-4.88 vs -1.7 pioglitazone mmol/L @ 30wk*5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -87.94 mg/dL as posted
-4.71 vs -1.7 pioglitazone mmol/L @ 30wk*5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -84.77 mg/dL as posted
-6.01 vs -2.47 Sitagliptin mmol/L @ 8wk*h,b,l
NCT00729326 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -108.35 mg/dL as posted
Dropout rate
7.3%m
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 57 more results
7.5%
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—5 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
4.3%
NCT01243424 · Phase 3
0%
NCT02467478 · Phase 4 · registry result, not featured evidence
15%5 mg per day
NCT02372630 · Phase 4 · registry result, not featured evidence
24%
NCT01897532 · Phase 4 · registry result, not featured evidence
5.3%5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
—5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
—5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
0%Linagliptin In-hospital
NCT02004366 · Phase 4 · registry result, not featured evidence
—Linagliptin on Discharge
NCT02004366 · Phase 4 · registry result, not featured evidence
—Linagliptin+50%Glargine Dose on d/
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
—Linagliptin+80%Glargine Dose on d/
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
20%
NCT02350478 · Phase 4 · registry result, not featured evidence
0%
NCT01969084 · Phase 4 · registry result, not featured evidence
14%5 mg
NCT01512979 · Phase 4 · registry result, not featured evidence
11.9%5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination
4.1%5 mg once daily + metformin once daily
NCT01438814 · Phase 4 · registry result, not featured evidence · combination
5.8%
NCT02897349 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
3.8%5 mg
NCT01792518 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
—5 mg
NCT01708902 · Phase 3 · registry result, not featured evidence
9.9%5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
—5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
11.6%5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
—5 mg QD, then 2.5 mg / Metformin after week 12
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg / 1000 mg
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
9.7%2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
10.9%2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
6.8%2.5 mg / 500 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
22.2%5 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
28.6%5 mg + 15 mg / 5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
33.8%5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
27.8%5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
6.8%5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
9%5 mg
NCT01214239 · Phase 3 · registry result, not featured evidence
6.8%5 mg once daily
NCT01215097 · Phase 3 · registry result, not featured evidence
11.3%5 mg tablet
NCT00996658 · Phase 3 · registry result, not featured evidence
2.4%A-GI+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
3.7%Bigu+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
12.1%Glin+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
6.8%Glit+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
7.7%SU+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
24.5%5 mg
NCT01194830 · Phase 3 · registry result, not featured evidence
13.9%5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence
17%linagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
20.4%linagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
9.9%5 mg
NCT01084005 · Phase 3 · registry result, not featured evidence
21.2%
NCT00740051 · Phase 3 · registry result, not featured evidence
5.8%
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
5.4%
NCT00621140 · Phase 3 · registry result, not featured evidence
4.5%5 mg once daily
NCT01012037 · Phase 2 · registry result, not featured evidence
7.2%2.5 mg twice daily
NCT01012037 · Phase 2 · registry result, not featured evidence
74.6%100 mgn
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 37 more results
67.6%100 mg/100 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
69.1%200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
67.6%200 mg/200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
14.9%100 mg
NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3
9%
NCT02556918 · Phase 4 · registry result, not featured evidence
—100 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
0%
NCT02920918 · Phase 4 · registry result, not featured evidence
—Sitagliptin (Diabetics and Control
NCT02639637 · Phase 4 · registry result, not featured evidence
—Sitagliptin and Valsartan (Control
NCT02639637 · Phase 4 · registry result, not featured evidence · combination
—
NCT02256189 · Phase 4 · registry result, not featured evidence
—
NCT01859793 · Phase 4 · registry result, not featured evidence
0%
NCT02312063 · Phase 4 · registry result, not featured evidence
—Metformin and Sitagliptin
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
0.7%Sitagliptin + Glargine (Hospital)
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
0%50 mg
NCT02318693 · Phase 4 · registry result, not featured evidence
6.4%
NCT01907854 · Phase 4 · registry result, not featured evidence
—
NCT01686932 · Phase 4 · registry result, not featured evidence
10.8%BID + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
6.7%BID + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
6.2%OD + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
—Metformin Plus Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence · combination
—Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence
12.9%Sitagliptin + SSI Prn
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
—Sitagliptin and Glargine + SSI
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
3%
NCT01131182 · Phase 4 · registry result, not featured evidence
20.5%Exenatide + Placebo
NCT00870194 · Phase 4 · registry result, not featured evidence
10.9%Exenatide + Sitagliptin
NCT00870194 · Phase 4 · registry result, not featured evidence · combination
5.6%
NCT00686634 · Phase 4 · registry result, not featured evidence
—
NCT00729326 · Phase 4 · registry result, not featured evidence
2.5%100 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
1%
NCT01485614 · Phase 3 · registry result, not featured evidence
4.8%Sitagliptin/Metformin
NCT01760447 · Phase 3 · registry result, not featured evidence
10.6%Sitagliptin/Metformin XR
NCT01760447 · Phase 3 · registry result, not featured evidence
2.6%
NCT03115112 · Phase 3 · registry result, not featured evidence
1.3%
NCT02791490 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
2.9%m
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 57 more results
1.7%
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—5 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
—
NCT01243424 · Phase 3
—
NCT02467478 · Phase 4 · registry result, not featured evidence
—5 mg per day
NCT02372630 · Phase 4 · registry result, not featured evidence
10.3%
NCT01897532 · Phase 4 · registry result, not featured evidence
4%5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
—5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
—5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
—Linagliptin In-hospital
NCT02004366 · Phase 4 · registry result, not featured evidence
—Linagliptin on Discharge
NCT02004366 · Phase 4 · registry result, not featured evidence
—Linagliptin+50%Glargine Dose on d/
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
—Linagliptin+80%Glargine Dose on d/
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
—
NCT02350478 · Phase 4 · registry result, not featured evidence
0%
NCT01969084 · Phase 4 · registry result, not featured evidence
1.3%5 mg
NCT01512979 · Phase 4 · registry result, not featured evidence
1.3%5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination
0.9%5 mg once daily + metformin once daily
NCT01438814 · Phase 4 · registry result, not featured evidence · combination
2.9%
NCT02897349 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
2.2%5 mg
NCT01792518 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
—5 mg
NCT01708902 · Phase 3 · registry result, not featured evidence
4.2%5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
—5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
2%5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
—5 mg QD, then 2.5 mg / Metformin after week 12
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg / 1000 mg
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
6.9%2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
4.8%2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
1.4%2.5 mg / 500 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
3.7%5 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
7.9%5 mg + 15 mg / 5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
7.5%5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
4.5%5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
3.4%5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
2%5 mg
NCT01214239 · Phase 3 · registry result, not featured evidence
1.5%5 mg once daily
NCT01215097 · Phase 3 · registry result, not featured evidence
2.7%5 mg tablet
NCT00996658 · Phase 3 · registry result, not featured evidence
1.2%A-GI+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
2.4%Bigu+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
9.1%Glin+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
0%Glit+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
4.9%SU+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
1.8%5 mg
NCT01194830 · Phase 3 · registry result, not featured evidence
4%5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence
6.4%linagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
5.8%linagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
4.9%5 mg
NCT01084005 · Phase 3 · registry result, not featured evidence
2.6%
NCT00740051 · Phase 3 · registry result, not featured evidence
1.5%
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
1.5%
NCT00621140 · Phase 3 · registry result, not featured evidence
1.3%5 mg once daily
NCT01012037 · Phase 2 · registry result, not featured evidence
3.6%2.5 mg twice daily
NCT01012037 · Phase 2 · registry result, not featured evidence
2.3%100 mgn
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 37 more results
4.2%100 mg/100 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.9%200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
4%200 mg/200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.3%100 mg
NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3
—
NCT02556918 · Phase 4 · registry result, not featured evidence
—100 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
—
NCT02920918 · Phase 4 · registry result, not featured evidence
—Sitagliptin (Diabetics and Control
NCT02639637 · Phase 4 · registry result, not featured evidence
—Sitagliptin and Valsartan (Control
NCT02639637 · Phase 4 · registry result, not featured evidence · combination
—
NCT02256189 · Phase 4 · registry result, not featured evidence
—
NCT01859793 · Phase 4 · registry result, not featured evidence
—
NCT02312063 · Phase 4 · registry result, not featured evidence
—Metformin and Sitagliptin
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Sitagliptin + Glargine (Hospital)
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—50 mg
NCT02318693 · Phase 4 · registry result, not featured evidence
—
NCT01907854 · Phase 4 · registry result, not featured evidence
—
NCT01686932 · Phase 4 · registry result, not featured evidence
1.5%BID + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
1.5%BID + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
0%OD + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
—Metformin Plus Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence · combination
—Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence
—Sitagliptin + SSI Prn
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
—Sitagliptin and Glargine + SSI
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
—
NCT01131182 · Phase 4 · registry result, not featured evidence
7.9%Exenatide + Placebo
NCT00870194 · Phase 4 · registry result, not featured evidence
3.9%Exenatide + Sitagliptin
NCT00870194 · Phase 4 · registry result, not featured evidence · combination
—
NCT00686634 · Phase 4 · registry result, not featured evidence
—
NCT00729326 · Phase 4 · registry result, not featured evidence
—100 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
—
NCT01485614 · Phase 3 · registry result, not featured evidence
—Sitagliptin/Metformin
NCT01760447 · Phase 3 · registry result, not featured evidence
—Sitagliptin/Metformin XR
NCT01760447 · Phase 3 · registry result, not featured evidence
0.5%
NCT03115112 · Phase 3 · registry result, not featured evidence
—
NCT02791490 · Phase 3 · registry result, not featured evidence
Serious AEs
3.2%m
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 57 more results
3.4%
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
10.4%5 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
46.4%
NCT01243424 · Phase 3
7.1%
NCT02467478 · Phase 4 · registry result, not featured evidence
0%5 mg per day
NCT02372630 · Phase 4 · registry result, not featured evidence
37%
NCT01897532 · Phase 4 · registry result, not featured evidence
—5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
12.6%5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
25%5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
0.8%Linagliptin In-hospital
NCT02004366 · Phase 4 · registry result, not featured evidence
13%Linagliptin on Discharge
NCT02004366 · Phase 4 · registry result, not featured evidence
15.1%Linagliptin+50%Glargine Dose on d/
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
23.1%Linagliptin+80%Glargine Dose on d/
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
15%
NCT02350478 · Phase 4 · registry result, not featured evidence
5.3%
NCT01969084 · Phase 4 · registry result, not featured evidence
1.3%5 mg
NCT01512979 · Phase 4 · registry result, not featured evidence
1.9%5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination
0.6%5 mg once daily + metformin once daily
NCT01438814 · Phase 4 · registry result, not featured evidence · combination
9.6%
NCT02897349 · Phase 3 · registry result, not featured evidence
5.2%25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
0.9%10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
9.3%5 mg
NCT01792518 · Phase 3 · registry result, not featured evidence
3.6%25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
4.5%10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
0%5 mg
NCT01708902 · Phase 3 · registry result, not featured evidence
—5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
1.4%5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
1.4%5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
3.2%5 mg QD, then 2.5 mg / Metformin after week 12
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
1.5%2.5 mg / 1000 mg
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
1.4%2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
2.7%2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
0.7%2.5 mg / 500 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
6.7%5 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
7.1%5 mg + 15 mg / 5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
11.3%5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
7.5%5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
24.8%5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
0.5%5 mg
NCT01214239 · Phase 3 · registry result, not featured evidence
2%5 mg once daily
NCT01215097 · Phase 3 · registry result, not featured evidence
2.2%5 mg tablet
NCT00996658 · Phase 3 · registry result, not featured evidence
8.2%A-GI+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
9.8%Bigu+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
7.6%Glin+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
2.7%Glit+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
4.9%SU+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
0.9%5 mg
NCT01194830 · Phase 3 · registry result, not featured evidence
13.8%5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence
8.2%linagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
5.3%linagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
8.6%5 mg
NCT01084005 · Phase 3 · registry result, not featured evidence
0.7%
NCT00740051 · Phase 3 · registry result, not featured evidence
3.1%
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
3%
NCT00621140 · Phase 3 · registry result, not featured evidence
2.2%5 mg once daily
NCT01012037 · Phase 2 · registry result, not featured evidence
4%2.5 mg twice daily
NCT01012037 · Phase 2 · registry result, not featured evidence
7.7%100 mgn
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 37 more results
10.1%100 mg/100 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
10.6%200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
10%200 mg/200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.9%100 mg
NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3
80%
NCT02556918 · Phase 4 · registry result, not featured evidence
0%100 mg
NCT03267576 · Phase 4 · registry result, not featured evidence
5.3%
NCT02920918 · Phase 4 · registry result, not featured evidence
0%Sitagliptin (Diabetics and Control
NCT02639637 · Phase 4 · registry result, not featured evidence
0%Sitagliptin and Valsartan (Control
NCT02639637 · Phase 4 · registry result, not featured evidence · combination
0%
NCT02256189 · Phase 4 · registry result, not featured evidence
0%
NCT01859793 · Phase 4 · registry result, not featured evidence
0%
NCT02312063 · Phase 4 · registry result, not featured evidence
—Metformin and Sitagliptin
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
—Metformin and Sitagliptin + Glargi
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
7.2%Sitagliptin + Glargine (Hospital)
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
0%50 mg
NCT02318693 · Phase 4 · registry result, not featured evidence
3.4%
NCT01907854 · Phase 4 · registry result, not featured evidence
2%
NCT01686932 · Phase 4 · registry result, not featured evidence
3.6%BID + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
2.6%BID + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
2.1%OD + Sita + Met
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
0%Metformin Plus Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence · combination
0%Sitagliptin
NCT00820573 · Phase 4 · registry result, not featured evidence
3.7%Sitagliptin + SSI Prn
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
0%Sitagliptin and Glargine + SSI
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
0%
NCT01131182 · Phase 4 · registry result, not featured evidence
3.1%Exenatide + Placebo
NCT00870194 · Phase 4 · registry result, not featured evidence
4.7%Exenatide + Sitagliptin
NCT00870194 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00686634 · Phase 4 · registry result, not featured evidence
2.7%
NCT00729326 · Phase 4 · registry result, not featured evidence
4.2%100 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
10.5%
NCT01485614 · Phase 3 · registry result, not featured evidence
6.5%Sitagliptin/Metformin
NCT01760447 · Phase 3 · registry result, not featured evidence
6.7%Sitagliptin/Metformin XR
NCT01760447 · Phase 3 · registry result, not featured evidence
2.1%
NCT03115112 · Phase 3 · registry result, not featured evidence
1.3%
NCT02791490 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
m
hypoglycaemia 22.7% (placebo 14.8%)
upper respiratory tract infection 5.8% (placebo 9.1%)
hyperglycaemia 5.6% (placebo 8.7%)
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 50 more results
hyperglycaemia 5.2% (placebo 14.7%)
nasopharyngitis 5.2% (placebo 5.1%)
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
5 mg
hypoglycaemia 20.8% (placebo 12.1%)
headache 15.6% (placebo 15.5%)
blood ketone body increased 10.4% (placebo 3.4%)
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
nasopharyngitis 17.5%
hypertension 14.2%
hyperglycaemia 14%
NCT01243424 · Phase 3
hypoglycaemia 29.3% (placebo 28.8%)
hypertension 6.2% (placebo 6.7%)
hyperglycaemia 6% (placebo 6.9%)
NCT01897532 · Phase 4 · registry result, not featured evidence
5 mg
hypoglycaemia 33.8% (placebo 25.2%)
viral upper respiratory tract infection 7.3% (placebo 5.3%)
urinary tract infection 6.6% (placebo 6%)
NCT02240680 · Phase 4 · registry result, not featured evidence
5 mg
hypoglycaemia 38.5% (placebo 25.2%)
viral upper respiratory tract infection 21.2% (placebo 5.3%)
bronchitis 9.6% (placebo 2.6%)
NCT02240680 · Phase 4 · registry result, not featured evidence
infections 5.5%
renal 4.7%
surgical reintervention 4.7%
NCT02004366 · Phase 4 · registry result, not featured evidence
gastrointestinal 1.1%
musculoskeletal 1.1%
skin 1.1%
NCT02004366 · Phase 4 · registry result, not featured evidence
gastrointestinal 1.1%
hematologic 0%
infections 0%
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
gastrointestinal 0%
hematologic 0%
infections 0%
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
dorsal pain 5% (placebo 0%)
nausea 5% (placebo 4.3%)
toothache 5% (placebo 0%)
NCT02350478 · Phase 4 · registry result, not featured evidence
increased creatinine and bun, reduced gfr 5.3% (placebo 13.6%)
pneumonia 5.3% (placebo 0%)
cramping in the calf muscle during the graded exercise test 0% (placebo 4.5%)
NCT01969084 · Phase 4 · registry result, not featured evidence
5 mg
dyslipidaemia 14%
hyperglycaemia 12.7%
urinary tract infection 8.9%
NCT01512979 · Phase 4 · registry result, not featured evidence
5 mg + Metformin
dyslipidaemia 8.8%
headache 6.3%
urinary tract infection 6.3%
NCT01512979 · Phase 4 · registry result, not featured evidence · combination
5 mg once daily + metformin once daily
diarrhoea 18%
abdominal pain 6.7%
nausea 6.7%
NCT01438814 · Phase 4 · registry result, not featured evidence · combination
hypoglycaemia 17.3% (placebo 12.7%)
upper respiratory tract infection 13.5% (placebo 12.7%)
hyperuricaemia 5.8% (placebo 1%)
NCT02897349 · Phase 3 · registry result, not featured evidence
25 mg + 5 mg
viral upper respiratory tract infection 26.7% (placebo 22.2%)
blood ketone body increased 13.8% (placebo 10.2%)
back pain 6% (placebo 2.8%)
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
10 mg + 5 mg
viral upper respiratory tract infection 15% (placebo 22.2%)
back pain 2.8% (placebo 2.8%)
contusion 2.8% (placebo 0.9%)
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
5 mg
hypoglycaemia 13.2% (placebo 5.6%)
nasopharyngitis 7.1% (placebo 5.6%)
upper respiratory tract infection 2.2% (placebo 5.1%)
NCT01792518 · Phase 3 · registry result, not featured evidence
25 mg + 5 mg
nasopharyngitis 3.6% (placebo 7.3%)
lipase increased 2.7% (placebo 5.5%)
urinary tract infection 2.7% (placebo 6.4%)
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
10 mg + 5 mg
urinary tract infection 7.1% (placebo 6.4%)
nasopharyngitis 4.5% (placebo 7.3%)
lipase increased 3.6% (placebo 5.5%)
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
5 mg
diarrhoea 3%
hyperuricaemia 3%
dizziness 0%
NCT01708902 · Phase 3 · registry result, not featured evidence
5 mg QD
hyperglycaemia 16.9%
hyperuricaemia 5.6%
nasopharyngitis 5.6%
NCT01708902 · Phase 3 · registry result, not featured evidence
5 mg QD
hyperuricaemia 7.5%
hyperglycaemia 4.8%
upper respiratory tract infection 4.1%
NCT01708902 · Phase 3 · registry result, not featured evidence
5 mg QD, then 2.5 mg / Metformin after week 12
hyperuricaemia 19.4%
dizziness 6.5%
hyperglycaemia 6.5%
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
2.5 mg / 1000 mg
hyperuricaemia 6.2%
hyperglycaemia 3.1%
diarrhoea 1.5%
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
2.5 mg / 1000 mg BID
diarrhoea 5.6%
hyperuricaemia 5.6%
upper respiratory tract infection 5.6%
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
2.5 mg / 1000 mg BID
diarrhoea 9.5%
hyperuricaemia 7.5%
upper respiratory tract infection 7.5%
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
2.5 mg / 500 mg BID
upper respiratory tract infection 8.2%
hyperuricaemia 5.4%
diarrhoea 4.8%
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
5 mg
hyperglycaemia 10.4%
nasopharyngitis 7.4%
hypertension 6.7%
NCT01183013 · Phase 3 · registry result, not featured evidence
5 mg + 15 mg / 5 mg + 30 mg
diarrhoea 7.9%
nasopharyngitis 7.1%
back pain 6.3%
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
5 mg + 30 mg
oedema 9%
dizziness 6.8%
oedema peripheral 6.8%
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
5 mg + 45 mg
oedema peripheral 11.3%
back pain 9%
urinary tract infection 5.3%
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
5 mg
hypoglycaemia 59.3%
nasopharyngitis 18.6%
hyperglycaemia 17.7%
NCT01087502 · Phase 3 · registry result, not featured evidence
5 mg
hyperlipidaemia 5.5% (placebo 3%)
hyperglycaemia 2% (placebo 4%)
NCT01214239 · Phase 3 · registry result, not featured evidence
5 mg once daily
hyperglycaemia 4.9% (placebo 5%)
hyperlipidaemia 4.4% (placebo 4%)
diarrhoea 2.4% (placebo 1%)
NCT01215097 · Phase 3 · registry result, not featured evidence
5 mg tablet
anaemia 7.1% (placebo 6.7%)
hyperglycaemia 6% (placebo 7.9%)
hypoglycaemia 5.5% (placebo 4.5%)
NCT00996658 · Phase 3 · registry result, not featured evidence
nasopharyngitis 41.2%
back pain 5.9%
constipation 5.9%
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 36.6%
bronchitis 11%
arthralgia 6.1%
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 45.5%
pharyngitis 7.6%
constipation 4.5%
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 33.8%
upper respiratory tract inflammation 8.1%
arthralgia 5.4%
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 31.5%
hypoglycaemia 14%
contusion 7%
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
5 mg
urinary tract infection 6.6% (placebo 3.3%)
hyperglycaemia 2.8% (placebo 9.2%)
NCT01194830 · Phase 3 · registry result, not featured evidence
5 mg
hypoglycaemia 30.3% (placebo 31.3%)
hyperglycaemia 14.3% (placebo 17.8%)
nasopharyngitis 11.3% (placebo 9.8%)
NCT00954447 · Phase 3 · registry result, not featured evidence
linagliptin 2.5 mg bid + metformin 1000 mg bid
diabetes mellitus 9.9%
diarrhoea 7%
nasopharyngitis 7%
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
linagliptin 2.5 mg bid + metformin 500 mg bid
hyperglycaemia 12.9%
diabetes mellitus 8%
glomerular filtration rate decreased 6.2%
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
5 mg
hypoglycaemia 22.8% (placebo 16.5%)
nasopharyngitis 10.5% (placebo 8.9%)
diarrhoea 5.6% (placebo 2.5%)
NCT01084005 · Phase 3 · registry result, not featured evidence
hyperglycaemia 14.6%
nasopharyngitis 9.9%
dizziness 7.3%
NCT00740051 · Phase 3 · registry result, not featured evidence
nasopharyngitis 9.3% (placebo 8.5%)
upper respiratory tract infection 3.5% (placebo 7.7%)
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
hyperglycaemia 8.6% (placebo 22.8%)
NCT00621140 · Phase 3 · registry result, not featured evidence
100 mgn
upper respiratory tract infection 13.1%
dizziness 11.5%
nasopharyngitis 9.2%
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 30 more results
100 mg/100 mg
upper respiratory tract infection 15.1%
dizziness 10.5%
nasopharyngitis 8.8%
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
200 mg
upper respiratory tract infection 11.4%
arthralgia 9.8%
blood glucose increased 8.9%
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
200 mg/200 mg
upper respiratory tract infection 16.4%
dizziness 12.4%
influenza 8.8%
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
100 mg
any infections and infestations 6.3% (placebo 3.4%)
upper respiratory tract infection 6.3% (placebo 3.4%)
any nervous system disorders 5.1% (placebo 3.9%)
NCT00086502 · Phase 3 · combination · Type 2 Diabetes · phase 3
infection 2% (placebo 2%)
headache 1% (placebo 1%)
loss of appetite 1% (placebo 0%)
NCT02556918 · Phase 4 · registry result, not featured evidence
100 mg
headache 1.6%
hypertension 1.6%
diarrhoea 0%
NCT03267576 · Phase 4 · registry result, not featured evidence
acute kidney injury 15.8%
arrhythmic events 5.3%
genital infection 5.3%
NCT02920918 · Phase 4 · registry result, not featured evidence
light-headedness 7.7% (placebo 7.7%)
paresthesias 7.7% (placebo 0%)
nausea 0% (placebo 7.7%)
NCT02639637 · Phase 4 · registry result, not featured evidence
light-headedness 0% (placebo 7.7%)
nausea 0% (placebo 7.7%)
paresthesias 0% (placebo 0%)
NCT02639637 · Phase 4 · registry result, not featured evidence · combination
rash 0% (placebo 2.8%)
NCT01859793 · Phase 4 · registry result, not featured evidence
hypoglycemia 0%
NCT02312063 · Phase 4 · registry result, not featured evidence
urinary tract infection 1.4%
wound infection 0%
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
50 mg
erythema 38.5%
hypoglycaemia 7.7%
periodontitis 7.7%
NCT02318693 · Phase 4 · registry result, not featured evidence
diarrhoea 9.3%
nausea 7.8%
upper respiratory tract infection 6.4%
NCT01907854 · Phase 4 · registry result, not featured evidence
hypoglycaemia 14%
blood glucose decreased 6%
NCT01686932 · Phase 4 · registry result, not featured evidence
influenza 5.7%
nasopharyngitis 4.7%
diarrhoea 4.2%
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
headache 5.7%
nasopharyngitis 5.7%
influenza 2.6%
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 5.3%
influenza 5.3%
headache 4.2%
NCT01519674 · Phase 4 · registry result, not featured evidence · combination
hyperglycemia 11.1%
pressure ulcer/skin ulcer 11.1%
hypoglycemia 3.7%
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
hypoglycemia 6.9%
pneumonia 6.9%
urinary tract infection 6.9%
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
headache 4.9%
dizziness 3.9%
hyperhidrosis 3.7%
NCT01131182 · Phase 4 · registry result, not featured evidence
nausea 15.7%
vomiting 10.2%
nasopharyngitis 8.7%
NCT00870194 · Phase 4 · registry result, not featured evidence
nausea 10.2%
nasopharyngitis 7.8%
headache 7%
NCT00870194 · Phase 4 · registry result, not featured evidence · combination
nausea 37%
vomiting 20.5%
headache 12.3%
NCT00729326 · Phase 4 · registry result, not featured evidence
100 mg
upper respiratory tract infection 7.8%
diarrhoea 4.5%
nausea 3.9%
NCT04017832 · Phase 3 · registry result, not featured evidence
hypoglycaemia 16.8%
nasopharyngitis 15.8%
upper respiratory tract infection 12.6%
NCT01485614 · Phase 3 · registry result, not featured evidence
hypoglycaemia 16.1%
upper respiratory tract infection 14.5%
diarrhoea 11.3%
NCT01760447 · Phase 3 · registry result, not featured evidence
hypoglycaemia 20%
upper respiratory tract infection 11.1%
abdominal pain 8.9%
NCT01760447 · Phase 3 · registry result, not featured evidence
nasopharyngitis 13%
hypoglycemia 5.2%
influenza 5.2%
NCT03115112 · Phase 3 · registry result, not featured evidence
diarrhoea 7.9% (placebo 4.8%)
NCT02791490 · Phase 3 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cAssessment timepoints differ: 6 weeks versus 12 weeks.
  4. dAssessment timepoints differ: 54 weeks versus 24 weeks.
  5. eTreatment context has not been resolved for both arms.
  6. fAssessment timepoints differ: 54 weeks versus 26 weeks.
  7. gThe reported result categories differ.
  8. hTrial phases differ: Phase 4 versus Phase 3.
  9. iAssessment timepoints differ: 26 weeks versus 52 weeks.
  10. jAssessment timepoints differ: 26 weeks versus 54 weeks.
  11. kAssessment timepoints differ: 20 weeks versus 12 weeks.
  12. lAssessment timepoints differ: 8 weeks versus 30 weeks.
  13. mPopulation comparability has not been reviewed for 55 of these studies.
  14. nPopulation comparability has not been reviewed for 33 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Linagliptin

HbA1c Less Than 6 5 9.9% (n=115) vs 6.7% (n=120) Glimepiride @ 52wk5 mg
absolute value · percentage points
NCT01087502 · Phase 3 · registry result, not featured evidence
show 9 more results
6.1% (n=115) vs 5% (n=120) Glimepiride @ 12wk5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
13.1% (n=777) vs 4.2% (n=262) placebo @ 24wk
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
13.1% (n=778) vs 4.2% (n=262) placebo @ 24wk
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
10.4% (n=511) vs 2.3% (n=171) placebo @ 24wk
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
10.7% (n=513) vs 3.4% (n=175) placebo @ 24wk
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
17.5% (n=252) vs 14.1% (n=128) placebo @ 24wk
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
17.5% (n=252) vs 14.1% (n=128) placebo @ 24wk
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
10.6% (n=329) vs 4.9% (n=162) placebo @ 24wk
NCT00621140 · Phase 3 · registry result, not featured evidence
10.8% (n=333) vs 4.9% (n=163) placebo @ 24wk
NCT00621140 · Phase 3 · registry result, not featured evidence
HbA1c Reduction 0 5 58.2% (n=778) vs 30.2% (n=262) placebo @ 24wk
absolute value · percentage points
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
49.7% (n=513) vs 21.7% (n=175) placebo @ 24wk
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
PPG Increment Over FPG mg/dL -1.72 vs 0.61 placebo mmol/L @ 24wk
absolute value · mmol/L
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -30.9 mg/dL as posted
Treatment Failure 50% (n=6) vs 60% (n=5) placebo @ 26wk5 mg
responder rate · % of participants
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time to Treatment Failure 2.37 vs 2.16 placebo months5 mg
time to event · months
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to months from 72.167 days as posted
Fasting Plasma Glucose Change mg/dL 10.29 vs 15.7 placebo mg @ 26wk5 mg
absolute change · mg
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 4 more results
0.12 vs 15.7 placebo mg @ 26wk5 mg
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
-11.3 vs 0.2 placebo mg @ 24wk5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
12.4 vs 19.7 Glimepiride mg @ 432wk
NCT01243424 · Phase 3
-5.5 vs 0.7 placebo mg @ 24wk
NCT02897349 · Phase 3 · registry result, not featured evidence
Seated SBP 2.21 vs 1.3 placebo mmHg @ 26wk5 mg
absolute change · mmHg
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
5.16 vs 1.3 placebo mmHg @ 26wk5 mg
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
Seated DBP 2.26 vs 0.76 placebo mmHg @ 26wk5 mg
absolute change · mmHg
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
6.75 vs 0.76 placebo mmHg @ 26wk5 mg
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
MACE 3-point Composite 20.7% (n=3023) vs 21.2% (n=3010) Glimepiride @ 432wk
event count · % of participants
NCT01243424 · Phase 3
show 2 more results
11.8% (n=3023) vs 12% (n=3010) Glimepiride @ 432wk
NCT01243424 · Phase 3
12.4% (n=3494) vs 12.1% (n=3485) placebo
NCT01897532 · Phase 4 · registry result, not featured evidence
MACE 4-point Composite 23.4% (n=3023) vs 23.7% (n=3010) Glimepiride @ 432wk
event count · % of participants
NCT01243424 · Phase 3
HbA1c Less Than 7 Without Hypoglycemia and no Weight Gain 16% (n=3014) vs 10.2% (n=3000) Glimepiride @ 432wk
absolute value · percentage points
Maintenance
NCT01243424 · Phase 3
HbA1c Less Than 7 Without Weight Gain 17.4% (n=3014) vs 14.1% (n=3000) Glimepiride @ 432wk
absolute value · percentage points
Maintenance
NCT01243424 · Phase 3

+ 47 further endpoints in the CSV export.

Sitagliptin

PMG 2-hr Change mg/dL -48.9 vs -2.2 placebo mg/dL @ 24wk100 mg
absolute change · mg/dL
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
-56.3 vs -2.2 placebo mg/dL @ 24wk200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.9 vs -6.8 Metformin mg/dL @ 20wk
NCT01485614 · Phase 3 · registry result, not featured evidence
-1.7 vs -39.7 Metformin mg/dL @ 54wk
NCT01485614 · Phase 3 · registry result, not featured evidence
PMG 2-hr Change mg/dL -30.5 mg/dL @ 104wk100 mg/100 mg
absolute change · mg/dL
No placebo or comparator arm
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
-38.3 mg/dL @ 104wk100 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
-41.5 mg/dL @ 104wk200 mg/200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
-35.5 mg/dL @ 104wk200 mg
NCT00087516 · Phase 3 · combination · Type 2 Diabetes · phase 3
Hyperglycemia 83.5% (n=91) vs 74.7% (n=91) placebo @ 0.29wk
event count · % of participants
NCT02556918 · Phase 4 · registry result, not featured evidence · converted to % from 76 Participants as posted
show 1 more result
5.5% (n=91) vs 3.3% (n=91) placebo @ 0.29wk*
NCT02556918 · Phase 4 · registry result, not featured evidence · converted to % from 5 Participants as posted
Persistent Hyperglycemia 63.7% (n=91) vs 64.8% (n=91) placebo @ 1.43wk
event count · % of participants
NCT02556918 · Phase 4 · registry result, not featured evidence · converted to % from 58 Participants as posted
Glucose 148.7 vs 149.8 placebo mmol/L @ 0.29wk
absolute value · mmol/L
NCT02556918 · Phase 4 · registry result, not featured evidence
show 2 more results
154.2 vs 156.5 placebo mmol/L @ 1.43wk
NCT02556918 · Phase 4 · registry result, not featured evidence
9.5 vs 9.4 Basal Bolus mmol/L
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
Hyperglycemia Ge 300 mg/dL 22% (n=91) vs 13.2% (n=91) placebo @ 1.43wk
event count · % of participants
NCT02556918 · Phase 4 · registry result, not featured evidence · converted to % from 20 Participants as posted
Severe Hypoglycemia Event Incidence 0% vs 0% placebo @ 0.29wk
event rate · count
NCT02556918 · Phase 4 · registry result, not featured evidence
show 1 more result
0% vs 0% placebo @ 1.43wk
NCT02556918 · Phase 4 · registry result, not featured evidence
Peak VO2 Change mL/Min -0.53 vs 0.67 Canagliflozin kg @ 12wk
absolute change · kg
NCT02920918 · Phase 4 · registry result, not featured evidence
Ventilatory Efficiency Change Slope -0.3 vs -0.3 Canagliflozin Unitless @ 12wk
absolute change · Unitless
NCT02920918 · Phase 4 · registry result, not featured evidence
FMD 5.8% (n=30) vs 6% (n=30) placebo @ 8wk
absolute change · percentage points
Following 8 weeks of therapy
NCT01859793 · Phase 4 · registry result, not featured evidence
Time in Tight Range 30.7% (n=138) vs 29.7% (n=139) Basal Bolus
absolute value · percentage points
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
Time in Range 57% (n=138) vs 59.6% (n=139) Basal Bolus
absolute value · percentage points
NCT01845831 · Phase 4 · registry result, not featured evidence · combination
show 2 more results
36% (n=27) vs 43% (n=26) Glargine and Lispro @ 0.14wk
NCT01378117 · Phase 4 · registry result, not featured evidence · combination
43% (n=29) vs 43% (n=26) Glargine and Lispro @ 0.14wk
NCT01378117 · Phase 4 · registry result, not featured evidence · combination

+ 62 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Linagliptin's landscape · Sitagliptin's landscape